Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Swedish Orphan Biovitrum

Clinicaltrial registered27 Oct 2026

Swedish Orphan Biovitrum

27 Oct 2026: Trial registered · A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
27 Oct 2026
Title
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
Conditions
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
Phase
Phase 3
Study Type
Interventional
Status
Recruiting
Countries
Brazil, Canada, Finland, France, Germany, Italy, Saudi Arabia, Spain, Switzerland, United Kingdom
Country
Brazil
Reference
NCT07898774
Location
Brazil, Canada, Finland
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Swedish Orphan Biovitrum

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Swedish Orphan Biovitrum in our registers.

More from Brazil

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.